Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2708163 | 0.98 | KDM4E (0.52) | KDM4EKMT2APKMFFAR3PARP1 | |
| SCHEMBL24721423 | 0.86 | — | — | |
| SCHEMBL457922 | 0.81 | — | — | |
| Tert-Butyl Formate SCHEMBL27789519 | 0.80 | TDP1 (0.42) | KDM4EKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL31169689 | 0.78 | — | — | |
| SCHEMBL29881301 | 0.78 | KDM4E (0.42) | KDM4EKMT2APKMFFAR3PARP1 | |
| SCHEMBL894742 | 0.77 | KDM4E (0.40) | KDM4EKMT2AFFAR3CYP1A2 | |
| SCHEMBL1292520 | 0.77 | FFAR3 (0.65) | KDM4EKMT2AFFAR3PARP1PARP2 | |
| SCHEMBL15340982 | 0.76 | ALDH1A1 (0.43) | KDM4EKMT2APKMFFAR3TDP1 | |
| SCHEMBL1536078 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2535338-A1 | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile | Abbott Laboratories (US) | 2012-12-19 | — | — | EP | claimed |
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | claimed |
| CN-101454312-A | 2-Carbocyclic amino-4-imidazolyl pyrimidines as inhibitors of cell proliferation | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | CN | claimed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | claimed |
| CN-122079868-A | Synthesis method of N-alkoxycarbonyl-4-amino-4-alkylpiperidine | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250333418-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK AS (DK) | 2025-10-30 | — | — | US | disclosed |
| EP-4608835-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| CN-120129684-A | Purine compound, composition containing same and use thereof | 诺和诺德股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK A/S (DK) | 2025-05-08 | — | — | US | disclosed |
| CN-119301126-A | Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound | 诺和诺德股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4479402-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-12-25 | — | — | EP | disclosed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | KDM4E 2962/4885KMT2A 3306/4885PKM 2866/4885 |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3361/4885KMT2A 3816/4885PKM 3624/4885 |
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, TRPV1 | KDM4E 2777/4885KMT2A 3336/4885PKM 1041/4885 |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | KDM4E 3489/4885KMT2A 3664/4885PKM 3748/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3361/4885KMT2A 3816/4885PKM 3624/4885 |
| US-20250333418-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, P2RY1 | KDM4E 3616/4885KMT2A 3780/4885PKM 1600/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | KDM4E 3352/4885KMT2A 3785/4885PKM 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.